Scientific studies on Inuspheresis®

Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis

The study explores how therapeutic apheresis may help alleviate persistent Long-COVID symptoms. Researchers found that by filtering out specific blood components, including autoantibodies and inflammatory markers, patients experienced improvements in energy levels, cognitive function, and overall well-being. This promising approach highlights a potential new avenue for managing Long-COVID and addressing lingering inflammation and immune dysregulation.

The study used therapeutic apheresis to filter out autoantibodies, lipids, and inflammatory markers from the blood of Long-COVID patients, assessing changes in clinical symptoms and biological markers before and after treatment.

Martin Achleitner, Charlotte Steenblock, Juliane Dänhardt, Natalia Jarzebska, Romina Kardashi, Waldemar Kanczkowski, Richard Straube, Roman N. Rodionov, Nitzan Bornstein, Sergey Tselmin, Frank Kaiser, Ronald Bucher, Mahmoud Barbir, Ma-Li Wong, Karin Voit-Bak, Julio Licinio & Stefan R. Bornstein

Long-COVID, Therapeutic Apheresis, Autoantibodies, Lipids, Inflammation, Biomarkers, INUSpheresis, Cytokines, Fibrinogen

Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

The study investigates how personalized apheresis treatments can reduce cardiovascular risks in patients with severe lipid disorders. Using advanced proteomic analysis, researchers examined the effectiveness of different apheresis filters in removing harmful proteins linked to heart disease. Findings suggest that tailoring apheresis protocols to individual patient needs could offer a targeted strategy to better manage cardiometabolic risk factors and improve heart health outcomes.

The study used the INUSpheresis system with different filters to analyze lipid and protein reduction in patients, using proteomic analysis to assess filter effectiveness.

X. Yin, K. Takov, R. Straube, K. Voit-Bak, J. Graessler, U. Julius, S. Tselmin, Roman N. Rodionov, M. Barbir, M. Walls, K. Theofilatos, M. Mayr, S.R. Bornstein

extracorporal apheresis
proteomics analysis
cardiovascular risk factors
precision medicine

Particles in the Eluate from Double Filtration Plasmapheresis – A Case Study Using Field Emission Scanning Electron Microscopy/Energy-Dispersive X-ray Spectroscopy (FE-SEM/EDX)

In this study, researchers employed advanced microscopy techniques to analyze the eluate from double filtration plasmapheresis (DFPP). Their findings revealed the presence of nano- and microparticles, providing insights into the composition of substances removed during DFPP treatments

The study used field emission scanning electron microscopy (FE-SEM) and energy-dispersive X-ray spectroscopy (EDX) to analyze and identify nano- and microparticles in the eluate from double filtration plasmapheresis (DFPP).

Felix Scholkmann, Antonietta M. Gatti

Double Filtration Plasmapheresis (DFPP)
Eluate
Field Emission Scanning Electron Microscopy (FE-SEM)
Energy-Dispersive X-ray Spectroscopy (EDX)
Nano- and Microparticles

Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?

This study explores the potential of extracorporeal apheresis as a treatment for chronic post-COVID-19 syndrome and chronic fatigue syndrome. The authors investigate the similarities between these conditions, particularly the role of autoantibodies against neurotransmitter receptors, and discuss how apheresis might alleviate debilitating symptoms by reducing these autoantibodies. They found that apheresis could potentially improve symptoms by targeting inflammatory markers and immune dysregulation, offering a promising avenue for patients suffering from these persistent conditions.

The study reviewed literature to assess extracorporeal apheresis as a treatment for chronic post-COVID-19 and chronic fatigue syndrome by examining immune and inflammatory effects.

Stefan R Bornstein, Karin Voit-Bak, Timo Donate, Roman N Rodionov, Raul R Gainetdinov , Sergey Tselmin, Waldemar Kanczkowski, Gregor M Müller, Martin Achleitner, Jun Wang, Julio Licinio, Michael Bauer, Allan H Young, Sandrine Thuret , Nicole Bechmann, Richard Straube

Chronic post-COVID-19 syndrome
Chronic fatigue syndrome (CFS)
Extracorporeal apheresis
Double filtration plasmapheresis (DFPP)
Immune dysregulation
Autoimmunity
Inflammatory markers

Is There a Role for Environmental and Metabolic Factors Predisposing to Severe COVID-19?

This study investigates how environmental and metabolic factors, such as pollution, climate, obesity, and diabetes, may predispose individuals to severe COVID-19 outcomes. By reviewing existing research, the authors highlight potential links between these risk factors and COVID-19 severity, offering insights into preventive strategies and therapeutic approaches to mitigate these effects.

The authors conducted a comprehensive review of existing literature, focusing on how environmental and metabolic factors may contribute to severe COVID-19 outcomes.

Stefan R Bornstein, Karin Voit-Bak, Dieter Schmidt, Henning Morawietz, Alexander Benjamin Bornstein, Waldimir Balanzew, Ulrich Julius, Roman N Rodionov, Anne Maria Biener, Jun Wang, Klaus-Martin Schulte, Peter Krebs, Günter Vollmer, R Straube

COVID-19
Environmental Pollution
Metabolic Factors
Obesity
Diabetes
Cardiovascular Disease
Pollution
Socioeconomic Conditions

Lipid Profiles in Lyme Borreliosis: A Potential Role for Apheresis?

The study titled explores how lipid levels are affected in patients with Lyme borreliosis and examines whether apheresis could offer therapeutic benefits. Researchers analyzed lipid profiles and inflammatory markers in patients undergoing extracorporeal double filtration apheresis. Findings suggest that apheresis may reduce harmful lipids and improve symptoms, pointing to a potential new approach in managing chronic Lyme disease symptoms and reducing cardiovascular risk associated with this condition.

The study analyzed lipid profiles and inflammatory markers in Lyme disease patients before and after undergoing double filtration apheresis to evaluate its effects on lipid reduction and symptom improvement.

Richard Straube, Karin Voit-Bak, A Gor, Til Steinmeier, George P Chrousos, Bernhard Otto Boehm, Andreas L Birkenfeld, Mahmoud Barbir , Wladimir Balanzew, Stefan R Bornstein

Lyme Borreliosis
Lipid Profiles
Apheresis
Hyperlipidemia
Inflammation

Extracorporeal apheresis therapy for Alzheimer disease – targeting lipids, stress, and inflammation

This study explores an innovative approach to Alzheimer's treatment by targeting "metabolic inflammation" through extracorporeal apheresis, a blood-cleansing technique that removes harmful lipids, stress hormones, and inflammatory molecules. Early findings suggest that reducing these factors may help slow Alzheimer’s progression, offering a promising new avenue for treatment.

The study examines the use of extracorporeal apheresis to reduce proinflammatory lipids, cortisol, and other inflammatory molecules in Alzheimer's patients.

Stefan R Bornstein, Karin Voit-Bak, Peter Rosenthal, Sergey Tselmin, Ulrich Julius, Ulrike Schatz, Bernhard O Boehm, Sandrine Thuret, Gerd Kempermann, Heinz Reichmann, George P Chrousos, Julio Licinio, Ma-Li Wong, Andrew V Schally, Richard Straube

Alzheimer's Disease (AD)
Extracorporeal Apheresis
Metabolic Inflammation
Apolipoprotein E (ApoE)
Lipoprotein(a)